Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin.
暂无分享,去创建一个
R. Hebbel | R. J. Kelm | A. Panoskaltsis-Mortari | B. Blazar | A. Shet | A. Solovey | S. Choong | R. Kollander | L. Milbauer | R. Kelm | A. Panoskaltsis‐Mortari
[1] J. Panepinto,et al. Pathophysiology of Stroke in Sickle Cell Disease , 2004, Microcirculation.
[2] R. Osarogiagbon,et al. The Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic Vasculopathy , 2004, Microcirculation.
[3] H. Ueno,et al. Synergistic effect of sphingosine 1-phosphate on thrombin-induced tissue factor expression in endothelial cells. , 2003, Blood.
[4] A. Scarpa,et al. Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. , 2003, Blood.
[5] J. Bischof,et al. Transgenic sickle mice have vascular inflammation. , 2003, Blood.
[6] M. Rosenfeld,et al. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. , 2003, Atherosclerosis.
[7] N. Sugimoto,et al. Integral Role of RhoA Activation in Monocyte Adhesion–Triggered Tissue Factor Expression in Endothelial Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[8] R. Swerlick,et al. Regulation of tissue factor in microvascular dermal endothelial cells. , 2003, The Journal of investigative dermatology.
[9] M. Eto,et al. Modulation of coagulation and fibrinolytic pathways by statins. , 2003, Endothelium : journal of endothelial cell research.
[10] F. Luft,et al. Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. , 2003, Kidney international.
[11] K. Nakagawa,et al. Functional role of Egr-1 mediating VEGF-induced tissue factor expression in the retinal capillary endothelium , 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.
[12] P. Adegboyega,et al. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. , 2002, Human pathology.
[13] M. Díaz-Ricart,et al. Erythropoietin Triggers a Signaling Pathway in Endothelial Cells and Increases the Thrombogenicity of their Extracellular Matrices In Vitro , 2002, Thrombosis and Haemostasis.
[14] A. Fowler,et al. Atypical mechanism of NF-kappaB activation during reoxygenation stress in microvascular endothelium: a role for tyrosine kinases. , 2002, Free radical biology & medicine.
[15] L. Mazzolai,et al. Tissue Factor Activity Is Upregulated in Human Endothelial Cells Exposed to Oscillatory Shear Stress , 2002, Thrombosis and Haemostasis.
[16] T. Lüscher,et al. Statin Prevents Tissue Factor Expression in Human Endothelial Cells: Role of Rho/Rho-Kinase and Akt Pathways , 2002, Circulation.
[17] M. Pittelkow,et al. Suppression of tissue factor expression, cofactor activity, and metastatic potential of murine melanoma cells by the N‐terminal domain of adenovirus E1A 12S protein , 2002, Journal of cellular biochemistry.
[18] Bernd R Binder,et al. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. , 2002, Blood.
[19] M. Gladwin,et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[20] M. Gladwin,et al. Pathophysiology of a Sickle Cell Trait Mouse Model: Human αβS Transgenes with One Mouse β-Globin Allele , 2001 .
[21] D. Winter,et al. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. , 2001, The Journal of surgical research.
[22] T. Luther,et al. Tissue factor in the heart. Multiple roles in hemostasis, thrombosis, and inflammation. , 2001, Trends in cardiovascular medicine.
[23] J. Liao,et al. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[24] J. Eckman,et al. Thrombogenesis in sickle cell disease. , 2001, The Journal of laboratory and clinical medicine.
[25] R. Hebbel,et al. Modulation of endothelial cell activation in sickle cell disease: a pilot study. , 2001, Blood.
[26] B. Binder,et al. Specificity, diversity, and convergence in VEGF and TNF‐α signaling events leading to tissue factor up regulation via EGR‐1 in endothelial cells , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] G. Semenza. Oxygen-regulated transcription factors and their role in pulmonary disease , 2000, Respiratory research.
[28] M. Endres,et al. Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice , 2000, Stroke.
[29] R. Hebbel,et al. Amendment history : Erratum ( September 2000 ) Hypoxia / reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice , 2018 .
[30] G. Vercellotti,et al. Reperfusion injury pathophysiology in sickle transgenic mice. , 2000, Blood.
[31] JosephLoscalzo,et al. Regulation of Tissue Factor Expression in Human Microvascular Endothelial Cells by Nitric Oxide , 2000 .
[32] J. Loscalzo,et al. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. , 2000, Circulation.
[33] D. Anderson,et al. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. , 1999, Molecular cell.
[34] Robert P. Hebbel,et al. Sickle Cell Anemia as a Possible State of Enhanced Anti-Apoptotic Tone: Survival Effect of Vascular Endothelial Growth Factor on Circulating and Unanchored Endothelial Cells , 1999 .
[35] A. Girotti,et al. Low-density lipoprotein susceptibility to oxidation and cytotoxicity to endothelium in sickle cell anemia. , 1999, The Journal of laboratory and clinical medicine.
[36] B. Binder,et al. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. , 1999, Blood.
[37] N. Mackman,et al. Lipopolysaccharide Induction of Tissue Factor Expression in Rabbits , 1999, Infection and Immunity.
[38] ChengXiang Zhai,et al. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[39] C. Moertel,et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. , 1998, Blood.
[40] R. Hebbel,et al. Tissue factor expression by endothelial cells in sickle cell anemia. , 1998, The Journal of clinical investigation.
[41] K. Hatakeyama,et al. Expression of tissue factor and tissue factor pathway inhibitor in rats lungs with lipopolysaccharide-induced disseminated intravascular coagulation. , 1997, Laboratory investigation; a journal of technical methods and pathology.
[42] E. Rubin,et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. , 1997, Science.
[43] S. Basili,et al. Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia , 1997, The Lancet.
[44] P. Bitterman,et al. The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and potentiated by cyclophosphamide. , 1997, The Journal of clinical investigation.
[45] E. Tremoli,et al. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[46] F. Pavalko,et al. Vascular endothelial cell activation and permeability responses to thrombin. , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[47] J. Hofrichter,et al. A second generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity. , 1995, Blood.
[48] N. Mackman. Regulation of the tissue factor gene , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[49] J. van der Meer,et al. Tumor necrosis factor alpha-induced endothelial tissue factor is located on the cell surface rather than in the subendothelial matrix. , 1994, Blood.
[50] R. Hebbel,et al. Sickle Cell Disease: Basic Principles and Clinical Practice , 1994 .
[51] R. Nagel,et al. High expression of human beta S- and alpha-globins in transgenic mice: hemoglobin composition and hematological consequences. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[52] W. Kisiel,et al. Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface , 1992 .
[53] F. Ofosu,et al. Plasma factor VII and thrombin–antithrombin III levels indicate increased tissue factor activity in sickle cell patients , 1992, British journal of haematology.
[54] W. Kisiel,et al. Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface. , 1992, Blood.
[55] R. Francis,et al. Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. , 1989, Haemostasis.
[56] Y. Nemerson. Tissue factor and hemostasis. , 1988, Blood.